Liver Cancer (HCC)

Polydatin is especially interesting in hepatocellular carcinoma because it combines direct anticancer effects with evidence of lower toxicity in normal liver cells.

Overview

The HCC literature suggests selective toxicity toward tumour cells, apoptosis induction, and treatment-sensitising relevance.

Key findings

• Selectively inhibits proliferation of multiple HCC cell lines while sparing normal liver cells in comparative work

• Induces dose-dependent apoptosis with Bax/Bcl-2 shifts and caspase activation

• Inhibits proliferation, invasion, and migration

• Blocks AKT/STAT3-FOXO1 signalling in HCC models

• Sensitises liver cancer cells to doxorubicin and cisplatin

Practical interpretation

HCC is one of the more attractive biological settings for polydatin because tumour selectivity and liver-related context both matter clinically.

References

Polydatin Inhibits Hepatocellular Carcinoma Cell Proliferation and Sensitizes Doxorubicin and Cisplatin
https://pmc.ncbi.nlm.nih.gov/articles/PMC9856937/

Polydatin inhibits cell proliferation, invasion and migration, and induces apoptosis in hepatocellular carcinoma cell
https://pmc.ncbi.nlm.nih.gov/articles/PMC5856444/